biOasis Technologies, Inc. operates as a biopharmaceutical company. It focuses on research and development for the diagnosis and treatment of neurological disease and disorders such as brain cancers, neurodegenerative diseases, and metabolic disorders. Its products include the Transcend program as its proprietary carrier, p97 and imaging agents across the blood brain barrier. The company was founded by Robin B. Hutchison on November 3, 2006 and is headquartered in New Haven, CT.